2.88 USD
▼-0.04-1.37%
盘后 2.96 +2.64%
2026-09-15
市值
$205.56M
市盈率
—
EPS
-1.58
股息率
—
52 周区间
1.70 – 3.72
成交量
458.36K
Beta
0.97
目标价
10.83
52W 低 1.7052W 高 3.72
价格走势
公司简介
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com...